In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ev3 completes $156.5mm IPO

Executive Summary

Ev3 (cardiovascular devices) has netted $156.5mm with the initial public offering of 11.77mm common shares priced at $14 each. The company, which focuses on three endovascular markets--peripheral vascular, cardiovascular, and neurovascular--had hoped to bring in up to $230mm with the financing. Some ev3 shareholders also sold 36k common shares.

Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies